Abstract
The theoretical prediction of drug-decorated nanoparticles (DDNPs) has become a very important task in medical applications. For the current paper, Perturbation Theory Machine Learning (PTML) models were built to predict the probability of different pairs of drugs and nanoparticles creating DDNP complexes with anti-glioblastoma activity. PTML models use the perturbations of molecular descriptors of drugs and nanoparticles as inputs in experimental conditions. The raw dataset was obtained by mixing the nanoparticle experimental data with drug assays from the ChEMBL database. Ten types of machine learning methods have been tested. Only 41 features have been selected for 855,129 drug-nanoparticle complexes. The best model was obtained with the Bagging classifier, an ensemble meta-estimator based on 20 decision trees, with an area under the receiver operating characteristic curve (AUROC) of 0.96, and an accuracy of 87% (test subset). This model could be useful for the virtual screening of nanoparticle-drug complexes in glioblastoma. All the calculations can be reproduced with the datasets and python scripts, which are freely available as a GitHub repository from authors.
Highlights
Drug-decorated nanoparticles (DDNPs) have many medical applications, such as drug delivery systems for different types of chemical compounds [1,2]
Some nanomaterials have been proven to pass through the blood-brain barrier and remain in glioblastoma multiforme (GBM) tissues; they could be used to co-deliver a wide variety of antitumor drugs [3,4]
Perturbation Theory (PT) was used to consider that the variation of drug-nanoparticle complexes depends on perturbations of both nanoparticle and drug properties in specific experimental conditions
Summary
Drug-decorated nanoparticles (DDNPs) have many medical applications, such as drug delivery systems for different types of chemical compounds [1,2] These systems make it possible to study different combinations of drugs and nanoparticles designed to treat specific medical conditions. According to the World Health Organization, glioblastoma multiforme (GBM) is the most common and one of the most malignant central nervous system tumors. Treatment of this cancer is still being studied due to GBM’s location in the intracranial space and the presence of the blood-brain barrier, which has selective permeability to some drugs. Some nanomaterials have been proven to pass through the blood-brain barrier and remain in GBM tissues; they could be used to co-deliver a wide variety of antitumor drugs [3,4]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have